<DOC>
	<DOCNO>NCT00818571</DOCNO>
	<brief_summary>This study ass pharmacokinetics vildagliptin mild , moderate severe renal impair patient</brief_summary>
	<brief_title>Pharmacokinetics Vildagliptin Mild , Moderate Severe Renal Impaired Patients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients mild ( CrCl 50 â‰¤80 ml/min ) , moderate ( CrCl 30 &lt; 50 ml/min ) severe ( CrCl &lt; 30 ml/min ) renal function , preferably type 2 diabetic match healthy volunteer CrCl &gt; 80 ml/min Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes , acute metabolic diabetic complication , treatment DPP4 inhibitor 30 day prior baseline , renal transplant history Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>Diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>Galvus</keyword>
	<keyword>Eucreas</keyword>
</DOC>